OTC Pharmaceuticals in Italy
Published: August 2013 · Publisher: MarketLine
OTC Pharmaceuticals in Italy industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
OTC Pharmaceuticals in Italy industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Italy otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.
*The Italian OTC pharmaceuticals market had total revenues of $3,609.3m in 2012, representing a compound annual growth rate (CAGR) of 1.3% between 2008 and 2012.
*The cough and cold preparations segment was the market's most lucrative in 2012, with total revenues of $967.7m, equivalent to 26.8% of the market's overall value.
*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 1.3% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $3,855.4m by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Italy
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Italy
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Italy otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Italy economy
Key Questions Answered
What was the size of the Italy otc pharmaceuticals market by value in 2012?
What will be the size of the Italy otc pharmaceuticals market in 2017?
What factors are affecting the strength of competition in the Italy otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Italy's otc pharmaceuticals market?
OTC Pharmaceuticals in Italy industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Italy otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.
*The Italian OTC pharmaceuticals market had total revenues of $3,609.3m in 2012, representing a compound annual growth rate (CAGR) of 1.3% between 2008 and 2012.
*The cough and cold preparations segment was the market's most lucrative in 2012, with total revenues of $967.7m, equivalent to 26.8% of the market's overall value.
*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 1.3% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $3,855.4m by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Italy
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Italy
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Italy otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Italy economy
Key Questions Answered
What was the size of the Italy otc pharmaceuticals market by value in 2012?
What will be the size of the Italy otc pharmaceuticals market in 2017?
What factors are affecting the strength of competition in the Italy otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Italy's otc pharmaceuticals market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, Boehringer Ingelheim GmbH, Novartis AG and The Procter & Gamble Company
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market share 11
Market distribution 12
Market Outlook 13
Market value forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
Boehringer Ingelheim GmbH 24
Novartis AG 28
The Procter & Gamble Company 32
Macroeconomic Indicators 35
Country Data 35
Appendix 37
Methodology 37
Industry associations 38
Related research 38
LIST OF TABLES
Table 1: Italy OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Italy OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Italy OTC pharmaceuticals market geography segmentation: $ million, 2012 10
Table 4: Italy OTC pharmaceuticals market share: % share, by value, 2012 11
Table 5: Italy OTC pharmaceuticals market distribution: % share, by value, 2012 12
Table 6: Italy OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Table 7: Bayer AG: key facts 20
Table 8: Bayer AG: key financials ($) 21
Table 9: Bayer AG: key financials (€) 21
Table 10: Bayer AG: key financial ratios 22
Table 11: Boehringer Ingelheim GmbH: key facts 24
Table 12: Boehringer Ingelheim GmbH: key financials ($) 25
Table 13: Boehringer Ingelheim GmbH: key financials (€) 25
Table 14: Boehringer Ingelheim GmbH: key financial ratios 26
Table 15: Novartis AG: key facts 28
Table 16: Novartis AG: key financials ($) 29
Table 17: Novartis AG: key financial ratios 30
Table 18: The Procter & Gamble Company: key facts 32
Table 19: The Procter & Gamble Company: key financials ($) 33
Table 20: The Procter & Gamble Company: key financial ratios 33
Table 21: Italy size of population (million), 2008–12 35
Table 22: Italy gdp (constant 2000 prices, $ billion), 2008–12 35
Table 23: Italy gdp (current prices, $ billion), 2008–12 35
Table 24: Italy inflation, 2008–12 36
Table 25: Italy consumer price index (absolute), 2008–12 36
Table 26: Italy exchange rate, 2008–12 36
LIST OF FIGURES
Figure 1: Italy OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Italy OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Italy OTC pharmaceuticals market geography segmentation: % share, by value, 2012 10
Figure 4: Italy OTC pharmaceuticals market share: % share, by value, 2012 11
Figure 5: Italy OTC pharmaceuticals market distribution: % share, by value, 2012 12
Figure 6: Italy OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Italy, 2012 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Italy, 2012 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Italy, 2012 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Italy, 2012 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Italy, 2012 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Italy, 2012 19
Figure 13: Bayer AG: revenues & profitability 22
Figure 14: Bayer AG: assets & liabilities 23
Figure 15: Boehringer Ingelheim GmbH: revenues & profitability 26
Figure 16: Boehringer Ingelheim GmbH: assets & liabilities 27
Figure 17: Novartis AG: revenues & profitability 30
Figure 18: Novartis AG: assets & liabilities 31
Figure 19: The Procter & Gamble Company: revenues & profitability 34
Figure 20: The Procter & Gamble Company: assets & liabilities 34
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market share 11
Market distribution 12
Market Outlook 13
Market value forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
Boehringer Ingelheim GmbH 24
Novartis AG 28
The Procter & Gamble Company 32
Macroeconomic Indicators 35
Country Data 35
Appendix 37
Methodology 37
Industry associations 38
Related research 38
LIST OF TABLES
Table 1: Italy OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Italy OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Italy OTC pharmaceuticals market geography segmentation: $ million, 2012 10
Table 4: Italy OTC pharmaceuticals market share: % share, by value, 2012 11
Table 5: Italy OTC pharmaceuticals market distribution: % share, by value, 2012 12
Table 6: Italy OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Table 7: Bayer AG: key facts 20
Table 8: Bayer AG: key financials ($) 21
Table 9: Bayer AG: key financials (€) 21
Table 10: Bayer AG: key financial ratios 22
Table 11: Boehringer Ingelheim GmbH: key facts 24
Table 12: Boehringer Ingelheim GmbH: key financials ($) 25
Table 13: Boehringer Ingelheim GmbH: key financials (€) 25
Table 14: Boehringer Ingelheim GmbH: key financial ratios 26
Table 15: Novartis AG: key facts 28
Table 16: Novartis AG: key financials ($) 29
Table 17: Novartis AG: key financial ratios 30
Table 18: The Procter & Gamble Company: key facts 32
Table 19: The Procter & Gamble Company: key financials ($) 33
Table 20: The Procter & Gamble Company: key financial ratios 33
Table 21: Italy size of population (million), 2008–12 35
Table 22: Italy gdp (constant 2000 prices, $ billion), 2008–12 35
Table 23: Italy gdp (current prices, $ billion), 2008–12 35
Table 24: Italy inflation, 2008–12 36
Table 25: Italy consumer price index (absolute), 2008–12 36
Table 26: Italy exchange rate, 2008–12 36
LIST OF FIGURES
Figure 1: Italy OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Italy OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Italy OTC pharmaceuticals market geography segmentation: % share, by value, 2012 10
Figure 4: Italy OTC pharmaceuticals market share: % share, by value, 2012 11
Figure 5: Italy OTC pharmaceuticals market distribution: % share, by value, 2012 12
Figure 6: Italy OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Italy, 2012 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Italy, 2012 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Italy, 2012 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Italy, 2012 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Italy, 2012 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Italy, 2012 19
Figure 13: Bayer AG: revenues & profitability 22
Figure 14: Bayer AG: assets & liabilities 23
Figure 15: Boehringer Ingelheim GmbH: revenues & profitability 26
Figure 16: Boehringer Ingelheim GmbH: assets & liabilities 27
Figure 17: Novartis AG: revenues & profitability 30
Figure 18: Novartis AG: assets & liabilities 31
Figure 19: The Procter & Gamble Company: revenues & profitability 34
Figure 20: The Procter & Gamble Company: assets & liabilities 34
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.